Effect of Everolimus on Heterogenous Renal Cancer Cells Populations Including Renal Cancer Stem Cells
- PMID: 29508215
- DOI: 10.1007/s12015-018-9804-2
Effect of Everolimus on Heterogenous Renal Cancer Cells Populations Including Renal Cancer Stem Cells
Abstract
The aim of this study was to compare effect of everolimus on growth of different renal cell carcinoma (RCC) populations and develop experimental design to measure the early response of everolimus in clear cell RCC (ccRCC) cell lines including renal cancer stem cells. Effect of everolimus on RCC cell lines which include primary (786-0) and metastatic (ACHN) RCC cell lines as well as heterogenous populations of tumor cells of different histological RCC subtypes (clear cell RCC and papillary RCC) was measured when treated with everolimus in the range of 1-9 µM. Gene expression profiling using microarray was performed to determine the early response to everolimus in ccRCC cell lines after optimizing concentration of drug. Gene Set Enrichment Analysis (GSEA) was done which mainly focused on basic genes related to mTOR, hormonal and metabolic pathways. Everolimus acts on RCC cells in a dose-dependent manner. In all examined cell lines IC50 dose was possible to calculate after the third day of treatment. In ccRCC lines (parental and stem cell) everolimus changes expression of mTOR complexes elements and elements of related pathways when treated with optimized doses of drug. Characteristic expression profile for ccRCC cells at an early exposure time to everolimus is to elucidate. Wevarie include some basic observations derived from data analysis in the context of mechanism of action of drug with a view to better understand biology of renal cancer cells.
Keywords: Clear cell renal cell carcinoma; Everolimus; Experimental design; Renal cancer stem cells; Renal cell carcinoma.
Similar articles
-
Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management.BJU Int. 2011 Jul;108(2 Pt 2):E29-35. doi: 10.1111/j.1464-410X.2010.09794.x. Epub 2011 Mar 16. BJU Int. 2011. PMID: 21435154
-
Comparative Gene Expression Profiling of Primary and Metastatic Renal Cell Carcinoma Stem Cell-Like Cancer Cells.PLoS One. 2016 Nov 3;11(11):e0165718. doi: 10.1371/journal.pone.0165718. eCollection 2016. PLoS One. 2016. PMID: 27812180 Free PMC article.
-
Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.Eur Urol. 2016 May;69(5):866-74. doi: 10.1016/j.eururo.2015.10.049. Epub 2015 Nov 26. Eur Urol. 2016. PMID: 26626617 Free PMC article. Clinical Trial.
-
Future perspectives for mTOR inhibitors in renal cell cancer treatment.Future Oncol. 2015;11(5):801-17. doi: 10.2217/fon.14.303. Future Oncol. 2015. PMID: 25757683 Review.
-
Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.Adv Ther. 2010 Aug;27(8):495-511. doi: 10.1007/s12325-010-0045-2. Epub 2010 Jul 8. Adv Ther. 2010. PMID: 20623346 Review.
Cited by
-
Targeting of Lung Cancer Stem Cell Self-Renewal Pathway by a Small Molecule Verrucarin J.Stem Cell Rev Rep. 2019 Aug;15(4):601-611. doi: 10.1007/s12015-019-09874-7. Stem Cell Rev Rep. 2019. PMID: 30835047 Free PMC article.
-
Triple-negative expression (ALDH1A1-/CD133-/mutant p53-) cases in lung adenocarcinoma had a good prognosis.Sci Rep. 2022 Jan 27;12(1):1473. doi: 10.1038/s41598-022-05176-0. Sci Rep. 2022. PMID: 35087112 Free PMC article.
-
ACSNI: An unsupervised machine-learning tool for prediction of tissue-specific pathway components using gene expression profiles.Patterns (N Y). 2021 Jun 11;2(6):100270. doi: 10.1016/j.patter.2021.100270. eCollection 2021 Jun 11. Patterns (N Y). 2021. PMID: 34179848 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous